Cantor Fitzgerald reaffirmed its Overweight rating and $118.00 price target for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company specializing in rare diseases. Currently ...

Goldman Sachs reiterated its Buy rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares with a steady price target of $78.00. The firm's analyst highlighted Ultragenyx's fourth-quarter total ...

STOCKHOLM – 14 February 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Year-end Report January-December 2024. The full report is available on the Company's website.

Reports Q4 revenue $164.88M, consensus $158.71M. “We have created a next-generation rare disease company on a pathway to profitability with ...

“My favorite movie is The Big Lebowski, the Unbreakable Boy second and then Zack Snyder’s Justice League. If I ever had to meet any actor, it would be Christian Bale. My favorite comedy actor, The ...

Charlotte Proud, 33, was diagnosed with Brittle Bone Disease - osteogenesis imperfecta - at just two years old, and has ...

Mereo BioPharma shifts focus to rare diseases with setrusumab showing strong results for Osteogenesis Imperfecta. Learn more on MREO stock here.

Charlotte Proud, a Sunderland University apprentice born with Osteogenesis Imperfecta (Brittle Bone Disease), is determined to make a difference ...

When Columbus resident Jennifer Roberts’ family gets together for the holidays, they typically play a few games of bingo for ...

TLC seems particularly busy lately, announcing some new shows that take the channel in familiar directions and at least one ...

Jay and Pamela take on their health struggles while also gearing up for their wedding in new docuseries "Jay and Pamela," ...